A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral INCB039110 in Subjects With Stable, Chronic Plaque Psoriasis

Trial Profile

A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral INCB039110 in Subjects With Stable, Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Itacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 04 Oct 2013 Results of this study have been presented at the European Academy of Dermatology and Venereology, according to an Incyte Corporation media release.
    • 01 May 2013 Preliminary results expected in the second half of 2013, according to an Incyte Corporation media release.
    • 29 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top